Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia... von Pfeifer, H, Wassmann, B, Bethge, W, Dengler, J, Bornhäuser, M, Stadler, M, Beelen, D, Vucinic, V, Burmeister, T, Stelljes, M, Faul, C, Dreger, P, Kiani, A, Schäfer-Eckart, K, Schwerdtfeger, R, Lange, E, Kubuschok, B, Horst, H A, Gramatzki, M, Brück, P, Serve, H, Hoelzer, D, Gökbuget, N, Ottmann, O G

Volltext

Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib von Tanaka, C, Yin, O Q P, Sethuraman, V, Smith, T, Wang, X, Grouss, K, Kantarjian, H, Giles, F, Ottmann, O G, Galitz, L, Schran, H

Volltext

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leuk... von Pfeifer, H, Lange, T, Wystub, S, Wassmann, B, Maier, J, Binckebanck, A, Giagounidis, A, Stelljes, M, Schmalzing, M, Dührsen, U, Wunderle, L, Serve, H, Brück, P, Schmidt, A, Hoelzer, D, Ottmann, O G

Volltext

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia von SINGER, J. B, SHOU, Y, OTTMANN, O. G, GILES, F, KANTARJIAN, H. M, HSU, Y, ROBEVA, A. S, RAE, P, WEITZMAN, A, MEYER, J. M, DUGAN, M

Volltext

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase von Giles, F J, Kantarjian, H M, le Coutre, P D, Baccarani, M, Mahon, F-X, Blakesley, R E, Gallagher, N J, Gillis, K, Goldberg, S L, Larson, R A, Hochhaus, A, Ottmann, O G

Volltext

Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitativ... von Pfeifer, H., Cazzaniga, G., van der Velden, V. H. J., Cayuela, J. M., Schäfer, B., Spinelli, O., Akiki, S., Avigad, S., Bendit, I., Borg, K., Cavé, H., Elia, L., Reshmi, S. C., Gerrard, G., Hayette, S., Hermanson, M., Juh, A., Jurcek, T., Chillón, M. C., Homburg, C., Martinelli, G., Kairisto, V., Lange, T., Lion, T., Mueller, M. C., Pane, F., Rai, L., Damm-Welk, C., Sacha, T., Schnittger, S., Touloumenidou, T., Valerhaugen, H., Vandenberghe, P., Zuna, J., Serve, H., Herrmann, E., Markovic, S., van Dongen, J. J. M., Ottmann, O. G.

Volltext

The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogeno... von Mian, A A, Schüll, M, Zhao, Z, Oancea, C, Hundertmark, A, Beissert, T, Ottmann, O G, Ruthardt, M

Volltext

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome von Boehrer, S, Adès, L, Tajeddine, N, Hofmann, W K, Kriener, S, Bug, G, Ottmann, O G, Ruthardt, M, Galluzzi, L, Fouassier, C, Tailler, M, Olaussen, K A, Gardin, C, Eclache, V, de Botton, S, Thepot, S, Fenaux, P, Kroemer, G

Volltext

High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cel... von Pursche, S., Ottmann, O.G., Ehninger, G., Schleyer, E.

Volltext

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study von Giles, F J, le Coutre, P D, Pinilla-Ibarz, J, Larson, R A, Gattermann, N, Ottmann, O G, Hochhaus, A, Radich, J P, Saglio, G, Hughes, T P, Martinelli, G, Kim, D-W, Novick, S, Gillis, K, Fan, X, Cortes, J, Baccarani, M, Kantarjian, H M

Volltext

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial) von Bug, G, Burchert, A, Wagner, E-M, Kröger, N, Berg, T, Güller, S, Metzelder, S K, Wolf, A, Hünecke, S, Bader, P, Schetelig, J, Serve, H, Ottmann, O G

Volltext

Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR ABL von Mian, A A, Oancea, C, Zhao, Z, Ottmann, O G, Ruthardt, M

Volltext

Compensatory PI3-kinase Akt mTor activation regulates imatinib resistance development von BURCHERT, A, WANG, Y, CAI, D, VON BUBNOFF, N, PASCHKA, P, MÜLLER-BRÜSSELBACH, S, OTTMANN, O. G, DUYSTER, J, HOCHHAUS, A, NEUBAUER, A

Volltext

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia von Olavarria, E, Ottmann, O G, Deininger, M, Clark, R E, Bandini, G, Byrne, J, Lipton, J, Vitek, A, Michallet, M, Siegert, W, Ullmann, A, Wassmann, B, Niederwieser, D, Fischer, T

Volltext

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies von Jabbour, Elias, Ottmann, Oliver G, Deininger, Michael, Hochhaus, Andreas

Volltext

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C von MÜLLER, M. C, GATTERMANN, N, KRAUSE, S. W, NERL, C, SAYER, H. G, OTTMANN, O. G, WALLER, C, AULITZKY, W, LE COUTRE, P, FREUND, M, MERX, K, PASCHKA, P, LAHAYE, T, KÖNIG, H, KREIL, S, BERGER, U, GSCHAIDMEIER, H, HEHLMANN, R, HOCHHAUS, A, DEININGER, M. W. N, BERNDT, A, FRUEHAUF, S, NEUHAUER, A, FISCHER, T, HOSSFELD, D. K, SCHNELLER, F

Volltext

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse... von Pfeifer, H., Cazzaniga, G., van der Velden, V. H. J., Cayuela, J. M., Schäfer, B., Spinelli, O., Akiki, S., Avigad, S., Bendit, I., Borg, K., Cavé, H., Elia, L., Reshmi, S. C., Gerrard, G., Hayette, S., Hermanson, M., Juh, A., Jurcek, T., Chillón, M. C., Homburg, C., Martinelli, G., Kairisto, V., Lange, T., Lion, T., Mueller, M. C., Pane, F., Rai, L., Damm-Welk, C., Sacha, T., Schnittger, S., Touloumenidou, T., Valerhaugen, H., Vandenberghe, P., Zuna, J., Serve, H., Herrmann, E., Markovic, S., Dongen, J. J. M. van, Ottmann, O. G.

Volltext

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts von Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M, Ottmann, O G

Volltext

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies von DeAngelo, D J, Spencer, A, Bhalla, K N, Prince, H M, Fischer, T, Kindler, T, Giles, F J, Scott, J W, Parker, K, Liu, A, Woo, M, Atadja, P, Mishra, K K, Ottmann, O G

Volltext

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) von WASSMANN, B, PFEIFER, H, SCHEURING, U, KLEIN, S. A, GÖKBUGET, N, BINCKEBANCK, A, MARTIN, H, GSCHAIDMEIER, H, HOELZER, D, OTTMANN, O. G

Volltext